May 12, 2022 / 04:05PM GMT
Franklin Jarman – Goldman Sachs Group, Inc., Research Division – VP & Senior Analyst
Great. Thanks, everyone. We’ll go ahead and get started with our next panel. I am very excited to be sitting here with Bausch Health management team. We’ve got the CFO, Tom Vadaketh, here to my left. And to his left, we have Will Woodfield, the Treasurer of the company. So thank you, guys, very much for joining us today.
Questions and Answers:
Franklin Jarman – Goldman Sachs Group, Inc., Research Division – VP & Senior Analyst
So maybe just to start out, there’s obviously been a lot of focus and debate around the transaction and the separation of the Bausch + Lomb business from Bausch Pharma. And I think to just level set folks, I’d love to hear from you how you’re thinking about the pro forma cash flow story for Bausch Health, to start, and then maybe we can go into some of the debates around some of the exogenous factors that could potentially impact the cash flow going forward.
Thomas G. Vadaketh – Bausch Health Companies Inc. –
Source: gurufocus.com
